Abstract:Rationale COVID-19 is complicated by acute lung injury, and death in some individuals. It is caused by SARS-CoV-2 that requires the ACE2 receptor and serine proteases to enter airway epithelial cells (AECs). Objective To determine what factors are associated with ACE2 expression particularly in patients with asthma and chronic obstructive pulmonary disease (COPD). Methods We obtained upper and lower AECs from 145 people from two independent cohorts, aged 2-89, Newcastle (n=115), and from Perth (n= 30) Australia. The Newcastle cohort was enriched with people with asthma (n=37) and COPD (n=38). Gene expression for ACE2 and other genes potentially associated with SARS-CoV-2 cell entry were assessed by quantitative PCR, protein expression was confirmed with immunohistochemistry on endobronchial biopsies and cultured AECs. Results Increased gene expression of ACE2 was associated with older age (p=0.02) and male sex (p=0.03), but not pack-years smoked. When we compared gene expression between adults with asthma, COPD and healthy controls, mean ACE2 expression was lower in asthma (p=0.01). Gene expression of furin, a protease that facilitates viral endocytosis, was also lower in asthma (p=0.02), while ADAM-17, a disintegrin that cleaves ACE2 from the surface was increased (p=0.02). ACE2 protein levels were lower in endobronchial biopsies from asthma patients. Conclusions Increased ACE2 expression occurs in older people and males. Asthma patients have reduced expression. Altered ACE2 expression in the lower airway may be an important factor in virus tropism and may in part explain susceptibility factors and why asthma patients are not over-represented in those with COVID-19 complications. Impact ACE2 is the primary receptor for SARS-COV-2. We demonstrate that lower airway expression of ACE2 is increased in older adults and males. We also find that lower ACE2 expression in epithelial cells occurs in people with asthma and is associated with reduced Furin expression and increased ADAM-17 expression. This may explain at least in part the relative sparing of people with asthma from severe COVID-19 disease. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement Work was in part funded by NHMRC Australia ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Hunter New England Research and Ethics Committee All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes Non-identifiable data can be made available at request.

Asthma, COPD and SARS-CoV-2 infection (COVID-19): potential mechanistic insights

Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID‐19

The Serpin-tine Search for Factors Associated with COVID-19 Severity in Patients with Chronic Obstructive Pulmonary Disease

Effect of SARS-CoV-2 infection on asthma patients

Insights into potential mechanisms of asthma patients with COVID-19: A study based on the gene expression profiling of bronchoalveolar lavage fluid

Discovery of common molecular signatures and drug repurposing for COVID-19/Asthma comorbidity: ACE2 and multi-partite networks

ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19

COVID-19, COPD, and AECOPD: Immunological, Epidemiological, and Clinical Aspects

COVID-19, Asthma, and Inhaled Corticosteroids: Another Beneficial Effect of Inhaled Corticosteroids?

Asthma and COVID-19: a dangerous liaison?

Forthcoming complications in recovered COVID-19 patients with COPD and asthma; possible therapeutic opportunities

Dysregulation of COVID-19 related gene expression in the COPD lung

Network-based analysis between SARS-CoV-2 receptor ACE2 and common host factors in COVID-19 and asthma: Potential mechanistic insights

The effect of allergy and asthma as a comorbidity on the susceptibility and outcomes of COVID-19

Increased SARS-CoV-2 Infection, Protease, and Inflammatory Responses in Chronic Obstructive Pulmonary Disease Primary Bronchial Epithelial Cells Defined with Single-Cell RNA Sequencing

ACE2 Expression is Elevated in Airway Epithelial Cells from Older and Male Healthy Individuals but Reduced in Asthma

ACE2 Expression is elevated in Airway Epithelial Cells from aged and male donors but reduced in asthma

Bioinformatic analysis and preliminary validation of potential therapeutic targets for COVID-19 infection in asthma patients

Asthma and COVID-19; different entities, same outcome: a meta-analysis of 107,983 patients

Is Asthma An Exclusionary Condition For Sars-Cov-2 Infection In China? -The Relationship Between Asthma And Covid-19

SARS-CoV-2-Specific Adaptive Immunity in COVID-19 Survivors With Asthma